Digest Network Come funziona
Network
/
Società
De
Non verificato

Deciphera Pharmaceuticals Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

5 comunicati stampa

Guarda tutti i comunicati
17/11/2025
Multimedialità
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Deciphera Announces the Opening of a New Office in Zug, Switzerland
Fonte
Deciphera Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
12/11/2025
Multimedialità
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025
Fonte
Deciphera Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
18/10/2025
Multimedialità
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Fiere
Industria
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025
Fonte
Deciphera Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
17/09/2025
Oncologia
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Fonte
Deciphera Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
14/02/2025
Multimedialità
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Oncologia
Industria
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
Fonte
Deciphera Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0